INmune Bio to Attend the 2026 Maxim Growth Summit
Key Highlights
- ➤INmune Bio (INMB) will meet institutional investors at the October 12-14 Maxim Growth Summit
- ➤CEO David Moss will present on an Immunology & Inflammation Therapies panel October 14
- ➤CORDStrom targets UK MHRA filing in 2026 and EU EMA filing in 2027
- ➤XPro1595 is positioned for an integrated Phase 2b/3 Alzheimer’s registrational program
Expert Statements
David Moss, CEO of INmune Bio
“Company CEO David Moss will also be presenting on an Immunology & Inflammation Therapies Panel on Thursday Oct. 14(th) at 10:30am.”
BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, is excited to announce its participation in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.
INmune Bio will be meeting with institutional investors in one-on-one sessions and engaging with senior Maxim research analysts throughout the event. Company CEO David Moss will also be presenting on an Immunology & Inflammation Therapies Panel on Thursday Oct. 14(th) at 10:30am.
Get started
Create a free account to read the full story.